Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines (Q44394151)

2 December 2017

Dexrazoxane in combination with anthracyclines lead to a synergistic cytotoxic response in acute myelogenous leukemia cell lines (English)

1 reference

2 December 2017

0 references

1 reference

Michael Pearlman

1

1 reference

2 December 2017

David Jendiroba

2

1 reference

2 December 2017

Lance Pagliaro

3

1 reference

2 December 2017

Afsaneh Keyhani

4

1 reference

2 December 2017

Baoshun Liu

5

1 reference

2 December 2017

Emil J Freireich

6

1 reference

2 December 2017

1 July 2003

1 reference

2 December 2017

1 reference

2 December 2017

27

1 reference

2 December 2017

7

1 reference

2 December 2017

617-626

1 reference

2 December 2017

Cancer statistics, 2002

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Epidemiology of the childhood acute leukemias

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Acute leukemia. A prototype of disseminated cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

COLONY ASSAY FOR PROLIFERATIVE BLAST CELLS CIRCULATING IN MYELOBLASTIC LEUKÆMIA

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Oxidative destruction of DNA by the adriamycin-iron complex.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Hydroxyl radical production and DNA damage induced by anthracycline-iron complex

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Oxidative destruction of erythrocyte ghost membranes catalyzed by the doxorubicin-iron complex

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Differences in O2 reduction by the iron complexes of adriamycin and daunomycin: the importance of the sidechain hydroxyl group

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

The effect of dexrazoxane (ICRF-187) on doxorubicin- and daunorubicin-mediated growth inhibition of Chinese hamster ovary cells

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

ICRF-187 rescue in etoposide treatment in vivo. A model targeting high-dose topoisomerase II poisons to CNS tumors

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Delayed administration of dexrazoxane provides cardioprotection for patients with advanced breast cancer treated with doxorubicin-containing therapy

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

In vitro effects of dexrazoxane (Zinecard) and classical acute leukemia therapy: time to consider expanded clinical trials?

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Bisdioxopiperazine, (+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane (ICRF 187), enhances the antiproliferative effect of cisplatin on human ovarian cancer cells.

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

Reduction of daunomycin toxicity by razoxane

1 reference

https://api.crossref.org/works/10.1016%2FS0145-2126%2802%2900273-4

7 January 2021

10.1016/S0145-2126(02)00273-4

Identifiers

DOI

1 reference

2 December 2017

1 reference